黑龙江医学
黑龍江醫學
흑룡강의학
HEILONGJIANG MEDICAL JOURNAL
2015年
4期
431-432
,共2页
林菜梅%罗泽民%罗燕娜%李勇%池海波%陈洪毅
林菜梅%囉澤民%囉燕娜%李勇%池海波%陳洪毅
림채매%라택민%라연나%리용%지해파%진홍의
晚期胃癌%希罗达%顺铂%奥沙利铂%疗效
晚期胃癌%希囉達%順鉑%奧沙利鉑%療效
만기위암%희라체%순박%오사리박%료효
Advanced gastric cancer%Xeloda%Cisplatin%Oxaliplatin,Curative effect
目的:观察晚期胃癌患者接受不同化疗方案的治疗效果,以此为临床提供有效的治疗参考依据。方法取我院收治的64例晚期胃癌患者为本次研究对象,根据治疗方法不同将其均分为对照组与实验组,每组各32例,给予对照组顺铂与希罗达联合用药治疗,给予实验组患者奥沙利铂与希罗达联合用药治疗,观察两组治疗效果并作统计学分析。结果两组治疗效果无显著差异,不具有统计学意义(P>0.05);与对照组相比,实验组患者不良反应发生率更低,组间差异具有统计学意义(P<0.05)。结论在晚期胃癌的临床治疗方案中,奥沙利铂联合希罗达方案效果确切,安全有效,不良反应较少,值得临床推广使用。
目的:觀察晚期胃癌患者接受不同化療方案的治療效果,以此為臨床提供有效的治療參攷依據。方法取我院收治的64例晚期胃癌患者為本次研究對象,根據治療方法不同將其均分為對照組與實驗組,每組各32例,給予對照組順鉑與希囉達聯閤用藥治療,給予實驗組患者奧沙利鉑與希囉達聯閤用藥治療,觀察兩組治療效果併作統計學分析。結果兩組治療效果無顯著差異,不具有統計學意義(P>0.05);與對照組相比,實驗組患者不良反應髮生率更低,組間差異具有統計學意義(P<0.05)。結論在晚期胃癌的臨床治療方案中,奧沙利鉑聯閤希囉達方案效果確切,安全有效,不良反應較少,值得臨床推廣使用。
목적:관찰만기위암환자접수불동화료방안적치료효과,이차위림상제공유효적치료삼고의거。방법취아원수치적64례만기위암환자위본차연구대상,근거치료방법불동장기균분위대조조여실험조,매조각32례,급여대조조순박여희라체연합용약치료,급여실험조환자오사리박여희라체연합용약치료,관찰량조치료효과병작통계학분석。결과량조치료효과무현저차이,불구유통계학의의(P>0.05);여대조조상비,실험조환자불량반응발생솔경저,조간차이구유통계학의의(P<0.05)。결론재만기위암적림상치료방안중,오사리박연합희라체방안효과학절,안전유효,불량반응교소,치득림상추엄사용。
Objective To observe the treatment effect of different chemotherapy schemes in the patients with advanced gastric cancer so as to provide effective reference for clinical application .Methods In the present study , 64 cases of advanced gastric cancer patients admit-ted to the hospital were served as the research subjects .According to the different treatment methods , the patients were divided into the con-trol group and the experimental group with 32 cases in each group , of which the combined cisplatin and shiroda were treated on the control group, and the combined oxaliplatin and xeloda were treated on the experimental group .The therapeutic effect of the two groups was ob-served, and statistical analysis was conducted .Results There was no significant difference in the therapeutic effect of the two groups , which showed no statistical significance (P>0.05).Compared with that of the control group , the patients in the experimental group had lower adverse reaction rate, and the differences between the two groups were statistically significant (P<0.05).Conclusion In the clini-cal treatment schemes of advanced gastric cancer , the scheme of oxaliplatin combined with xeloda has definite effect , and it is safe and effective and less adverse reactions , so it is worthy of clinical promotion and application .